Guardant Health, Inc.

Guardant Health is a precision oncology company that develops and provides blood-based and tissue-based diagnostic tests for cancer detection, profiling, and monitoring. The company's core offering, the Guardant360 liquid biopsy platform, analyzes circulating tumor DNA to identify tumor mutations across 740+ genes and supports guideline-recommended biomarkers for treatment selection. The company also offers Shield, a blood-based colorectal cancer screening test for asymptomatic adults, and Guardant Reveal, which detects circulating tumor DNA at the molecular level for early cancer detection. The Guardant360 Tissue test performs molecular profiling of tumor tissue samples, while additional research-focused assays including GuardantINFINITY and GuardantOMNI serve cancer research and therapy development applications.

Beyond testing services, Guardant Health provides a suite of software and data solutions. GuardantINFORM offers longitudinal tracking of tumor evolution and clinical outcomes, while GuardantConnect links patients with actionable molecular alterations to relevant clinical trials. The company's Smart Platform delivers multiomic insights combining genomic, epigenomic, and RNA-based data for research and clinical applications. The company also generates revenue through development services, including companion diagnostic development, clinical trial support, testing methodology development, technology licensing, and kit fulfillment.

Headquartered in Palo Alto, California, Guardant Health operates with approximately 2,490 full-time employees and serves customers across the United States and internationally. The company was incorporated in Delaware in 2011.